Boston Scientific Indefinite-Lived Research and Development Assets decreased by 5.3% to $770.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 719.1%, from $94.00M to $770.00M. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows an upward trend with a 16.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $330.00M | $374.00M | $246.00M | $246.00M | $232.00M | $232.00M | $232.00M | $232.00M | $174.00M | $174.00M | $174.00M | $174.00M | $214.00M | $94.00M | $94.00M | $94.00M | $813.00M | $813.00M | $813.00M | $770.00M |
| QoQ Change | — | +13.3% | -34.2% | +0.0% | -5.7% | +0.0% | +0.0% | +0.0% | -25.0% | +0.0% | +0.0% | +0.0% | +23.0% | -56.1% | +0.0% | +0.0% | +764.9% | +0.0% | +0.0% | -5.3% |
| YoY Change | — | — | — | — | -29.7% | -38.0% | -5.7% | -5.7% | -25.0% | -25.0% | -25.0% | -25.0% | +23.0% | -46.0% | -46.0% | -46.0% | +279.9% | +764.9% | +764.9% | +719.1% |